Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects
This review aims to present completed clinical trial data surrounding the medicinal benefits and potential side effects of the increasingly popular cannabidiol (CBD)-based drug products, specifically Epidiolex. The article is divided into two sections based on if the ailment being treated by this ca...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00063/full |
| _version_ | 1811274276660051968 |
|---|---|
| author | Christopher S. Pauli Matthieu Conroy Brian D. Vanden Heuvel Sang-Hyuck Park Sang-Hyuck Park |
| author_facet | Christopher S. Pauli Matthieu Conroy Brian D. Vanden Heuvel Sang-Hyuck Park Sang-Hyuck Park |
| author_sort | Christopher S. Pauli |
| collection | DOAJ |
| description | This review aims to present completed clinical trial data surrounding the medicinal benefits and potential side effects of the increasingly popular cannabidiol (CBD)-based drug products, specifically Epidiolex. The article is divided into two sections based on if the ailment being treated by this cannabinoid is classified as either physiological or neurological conditions. In addition to describing the current status, we also examined the different primary and secondary outcomes recorded for each study, which varies greatly depending on the funding source of the clinical trial. With the recent FDA-approval of Epidiolex, this review mainly focused on trials involving this specific formulation since it is the only CBD-based drug currently available to clinicians, although all other clinically trialed CBD(A) drugs were also examined. We hope this review will help guide future research and clinical trials by providing the various outcomes measured in a single review. |
| first_indexed | 2024-04-12T23:16:06Z |
| format | Article |
| id | doaj.art-5b4837fd576e481ba1d6ebce6eab311d |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T23:16:06Z |
| publishDate | 2020-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-5b4837fd576e481ba1d6ebce6eab311d2022-12-22T03:12:40ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-02-011110.3389/fphar.2020.00063505190Cannabidiol Drugs Clinical Trial Outcomes and Adverse EffectsChristopher S. Pauli0Matthieu Conroy1Brian D. Vanden Heuvel2Sang-Hyuck Park3Sang-Hyuck Park4Institute of Cannabis Research, Colorado State University-Pueblo, Pueblo, CO, United StatesInstitute of Cannabis Research, Colorado State University-Pueblo, Pueblo, CO, United StatesDepartment of Biology, Colorado State University-Pueblo, Pueblo, CO, United StatesInstitute of Cannabis Research, Colorado State University-Pueblo, Pueblo, CO, United StatesDepartment of Biology, Colorado State University-Pueblo, Pueblo, CO, United StatesThis review aims to present completed clinical trial data surrounding the medicinal benefits and potential side effects of the increasingly popular cannabidiol (CBD)-based drug products, specifically Epidiolex. The article is divided into two sections based on if the ailment being treated by this cannabinoid is classified as either physiological or neurological conditions. In addition to describing the current status, we also examined the different primary and secondary outcomes recorded for each study, which varies greatly depending on the funding source of the clinical trial. With the recent FDA-approval of Epidiolex, this review mainly focused on trials involving this specific formulation since it is the only CBD-based drug currently available to clinicians, although all other clinically trialed CBD(A) drugs were also examined. We hope this review will help guide future research and clinical trials by providing the various outcomes measured in a single review.https://www.frontiersin.org/article/10.3389/fphar.2020.00063/fullcannabidiol (CBD)cannabidiolic acid (CBDA)cannabinoidsclinical trialEpidiolexhemp |
| spellingShingle | Christopher S. Pauli Matthieu Conroy Brian D. Vanden Heuvel Sang-Hyuck Park Sang-Hyuck Park Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects Frontiers in Pharmacology cannabidiol (CBD) cannabidiolic acid (CBDA) cannabinoids clinical trial Epidiolex hemp |
| title | Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects |
| title_full | Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects |
| title_fullStr | Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects |
| title_full_unstemmed | Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects |
| title_short | Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects |
| title_sort | cannabidiol drugs clinical trial outcomes and adverse effects |
| topic | cannabidiol (CBD) cannabidiolic acid (CBDA) cannabinoids clinical trial Epidiolex hemp |
| url | https://www.frontiersin.org/article/10.3389/fphar.2020.00063/full |
| work_keys_str_mv | AT christopherspauli cannabidioldrugsclinicaltrialoutcomesandadverseeffects AT matthieuconroy cannabidioldrugsclinicaltrialoutcomesandadverseeffects AT briandvandenheuvel cannabidioldrugsclinicaltrialoutcomesandadverseeffects AT sanghyuckpark cannabidioldrugsclinicaltrialoutcomesandadverseeffects AT sanghyuckpark cannabidioldrugsclinicaltrialoutcomesandadverseeffects |